User:Mr. Ibrahem/Gallium (68Ga) gozetotide

Gallium (68Ga) gozetotide, sold under the brand name Illuccix, is a radioactive diagnostic agent used for imaging prostate cancer by positron emission tomography (PET). Specifically it is used in cases that are prostate-specific membrane antigen (PSMA) positive. It is given by injection into a vein.

Common side effects include nausea, diarrhea, and dizziness. Other side effects include radiation exposure. It is made of 68Ga attached to the prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx).

Gallium (68Ga) gozetotide was approved for medical use in the United States in 2020. As of 2022 it has been recommended for approval, but has not yet been approved in Europe. In the United Kingdom it costs the NHS about £2,000 per 25 ucg as of 2022.